NCT02783950Completed
Genomics in Michigan Impacting Observation or Radiation
Genomics in Michigan Impacting Observation or Radiation (G-MINOR)
Source: ClinicalTrials.gov · Last updated 26 Sept 2024
Brief summary (registry, in English)
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 356 (actual)
- First submitted
- 24 May 2016
- Start date
- 17 Jan 2017
- Primary completion date
- 1 Feb 2020
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT02783950
What you commit to
- Study type: Interventional
- Participants enrolled: 356
- From 17 Jan 2017 to the primary completion date, 1 Feb 2020
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who have any of the following will not be eligible to participate:
- Have regional or distant metastatic disease
- Received any radiation or hormone therapy (neo-adjuvant, adjuvant, or salvage)
- Node positive
Who the study is looking for
- Prostate cancer patients who have undergone radical prostatectomy
- PSA \< 0.1 ng/ml at enrollment
- At least one of the following:
- pT3 (seminal vesicle invasion or extraprostatic extension), or
- Positive surgical margins
- Radical prostatectomy within one year of enrollment
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Hospital and Health Systems Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Henry Ford Hospital Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Wayne State University/Karmanos Cancer Institute Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Michigan Urological Clinic Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Spectrum Health Medical Group- Urology Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Urology Associates of Grand Rapids Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Urology Surgeons, PC Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Urologic Consultants Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
| Comprehensive Medical Center PLLC Coordinator of this site? Confirm its status | Royal Oak | United States | Unknown status |
| Tri-City Urology Coordinator of this site? Confirm its status | Saginaw | United States | Unknown status |
| Bay Area Urology Associates, PC Coordinator of this site? Confirm its status | Traverse City | United States | Unknown status |
| Michigan Institute of Urology-Town Center Coordinator of this site? Confirm its status | Troy | United States | Unknown status |
| IHA Urology at St. Joe's Ann Arbor Coordinator of this site? Confirm its status | Ypsilanti | United States | Unknown status |
Related publications
- Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial.JNCI Cancer Spectr · 2026 · PMID 42026952
This page is information, not medical advice. Discuss any trial with your doctor.